Insull EA, et al. - In a small population, researchers tested the effectiveness of low dose rituximab in reducing clinical activity in thyroid eye disease (TED), an autoimmune inflammatory disease that can be disfiguring and potentially sight threatening. A retrospective audit was conducted primarily with a 100 mg infusion of rituximab in consecutive patients with active TED. If clinically indicated, additional glucocorticoid or steroid sparing agents were prescribed. Findings revealed that low-dose rituximab for active TED is an effective, well-tolerated and safe treatment. It reduces disease activity and reduces systemic steroid administration. The only adverse effect was a transient infusion-related rash.